Hydrochloric Acid

Hydrochloric Acid

SCHEMBL7280694

Cl.Nc1c(Cl)cc(C(=O)O)cc1C(F)(F)F

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
TTR known ✓ P02766 1/20 0.46
ADRB2 known ✓ P07550 7/20 0.43
ADRB1 known ✓ P08588 1/20 0.40
HSD11B1 known ✓ P28845 3/20 0.36
KDR known ✓ P35968 1/20 0.36
TSHR P16473 1/20 0.40
TPMT P51580 2/20 0.39
MRGPRX4 Q96LA9 1/20 0.39
PLAU P00749 1/20 0.39
SRD5A2 P31213 1/20 0.36
PDK1 Q15118 1/20 0.35
PDK2 Q15119 1/20 0.35
PDK3 Q15120 1/20 0.35
PDK4 Q16654 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3306839 0.98 TTR (0.47) TTRADRB2ADRB1TSHRTPMT
SCHEMBL5165740 0.84 ADRB2 (0.41) ADRB2ADRB1HSD11B1KDRPDK1
SCHEMBL28644289 0.83 ADRB2 (0.40) ADRB2ADRB1HSD11B1KDRPDK1
SCHEMBL5166345 0.83 NPFFR2 (0.44) ADRB2ADRB1HSD11B1KDRPDK1
SCHEMBL31749059 0.83 NPFFR2 (0.44) ADRB2ADRB1HSD11B1KDRPDK1
Hydrochloric Acid SCHEMBL11627207 0.81 TTR (0.60) TTRTSHRTPMTPLAUHSD11B1
Hydrochloric Acid SCHEMBL11632990 0.81 TTR (0.47) TTRADRB2TPMT
SCHEMBL12433188 0.80 ADRB2 (0.45) ADRB2ADRB1HSD11B1KDR
SCHEMBL9446664 0.80 ADRB2 (0.39) ADRB2ADRB1HSD11B1KDRPDK1
SCHEMBL285092 0.79 TTR (0.62) TTRTSHRTPMTPLAUHSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5273972-A [(2-diakylaminomethyl)-3-quinuclidinyl]-benzamides and benzoates A. H. ROBINS COMPANY, INCORPORATED (US) 1993-12-28 US disclosed
US-5236931-A Treating anxiety, psychosis, cognitive dysfunction, migrane, cluster headache, trigeminal neuralgia emesis and impaired gastric motility A. H. ROBINS COMPANY, INCORPORATED (US) 1993-08-17 US disclosed
US-5206246-A Anxiolytic agents A. H. ROBINS COMPANY, INCORPORATED (US) 1993-04-27 US disclosed
EP-0306345-B1 2-ALKOXY-N-(1-AZABICYCLO(2.2.2)-OCT-3-YL) BENZAMIDES AND THIOBENZAMIDES HAVING AN ANTISCHIZOPHRENIC ACTIVITY SYNTHELABO (FR) 1993-04-14 EP disclosed
EP-0353372-B1 Antischizophrenic-S-N-(1-azabicyclo[2.2.2.]oct-3-yl) benzamides and thiobenzamides SYNTHELABO (FR) 1993-02-03 EP disclosed
EP-0272052-B1 Anxiolytic-N-(1-Azabicyclo[2.2.2]Oct-3-yl) Benzamides and Thobenzamides A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) 1992-07-08 EP disclosed
US-5084460-A Psychological disorders, anxiolytic agents and cognition activators A. H. ROBINS COMPANY, INCORPORATED (US) 1992-01-28 US disclosed
US-5025022-A Method of treating or preventing schizophrenia and/or psychosis using S-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides A.H. ROBINS COMPANY, INCORPORATED A VA CORPORATION 1991-06-18 US disclosed
US-5017580-A Memory enhancing-R-N-(1-azabicyclo[2.2.2.]oct-3-yl)benzamides and thiobenzamides A.H. ROBINS COMPANY, INCORPORATED A VA CORPORATION 1991-05-21 US disclosed
US-4908370-A Antianxiety agents A. H. ROBBINS COMPANY, INC. (US) 1990-03-13 US disclosed
EP-0353371-A1 Memory enhancing-R-N-(1-azabicyclo[2.2.2] oct-3-yl) benzamides and thiobenzamides SYNTHELABO (FR) 1990-02-07 EP disclosed
EP-0353372-A1 Antischizophrenic-S-N-(1-azabicyclo[2.2.2.]oct-3-yl) benzamides and thiobenzamides SYNTHELABO (FR) 1990-02-07 EP disclosed
US-4877794-A 2-Alkoxy-n-(1-azabicyclo(2.2.2)oct-3-yl) benzamide and thiobenzamide compositions and the use thereof to treat schizophrenia A. H. ROBINS COMPANY, INCORPORATED (US) 1989-10-31 US disclosed
EP-0311724-A1 Anxiolytic-R-N-(1-azabicyclo[2.2.2]oct-3-yl) benzamides and thiobenzamides SYNTHELABO (FR) 1989-04-19 EP disclosed
EP-0272052-A1 Anxiolytic-N-(1-Azabicyclo[2.2.2]Oct-3-yl) Benzamides and Thobenzamides A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) 1988-06-22 EP disclosed
US-4717563-A 2-alkoxy-N-(1-azabicyclo(2.2.2)oct-3-yl) benzamides and thiobenzamides in a method for alleviating emesis caused by non-platinum anticancer drugs A. H. ROBINS COMPANY, INC. (US) 1988-01-05 US disclosed
EP-0240180-A1 2-alkoxy-N-(1-azabicyclo[2.2.2]-oct-3-yl) benzamides and thiobenzamides in the alleviation of emesis caused by non-platinum anticancer drugs SYNTHELABO (FR) 1987-10-07 EP disclosed
US-4593034-A 2-alkoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides A. H. ROBINS COMPANY, INC. (US) 1986-06-03 US disclosed
EP-0158532-A2 Use of 4-amino-N-(1-azabicyclo[2.2.2]oct-3-yl)-5-chloro-2-methoxybenzamide for the manufacture of a medicament having anti-emetic activity. SYNTHELABO (FR) 1985-10-16 EP disclosed
US-4093734-A ANTIULCER AGENTS, ANTIEMETICS, ANTICONVULSANTS BOEHRINGER INGELHEIM GMBH (DT) 1978-06-06 US disclosed